In Brief: FDA 515(i) reclassifications
This article was originally published in The Gray Sheet
Executive Summary
FDA 515(i) reclassifications: Agency plans to downclassify erythropoietin assays and fibrin monomer paracoagulation tests from Class III to Class II in February along with four or five other devices under Sec. 515(i) of the Safe Medical Devices Act of 1990, staffers say. Under the SMDA authority, manufacturers are required to respond to FDA's call for safety and effectiveness data for preamendments Class III devices that have not been subject to calls for premarket approval applications. Data for the devices covered by the upcoming reclassification proposals were due at FDA in August...
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.